Your Bextra Side Effects Lawyer - Bextra, Celebrex & Vioxx Side Effects FDA Transcript

Your Bextra side effects lawyer provides you the complete transcript of the February 17^th, 2005 joint meeting of the FDA's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. We have formatted the complete transcript of the three day conference for easy of navigation to provide you with the best possible bextra information. To contact a Bextra Lawyer, click here for a FREE case evaluation.

Conflict of Interest Statement

MS. TOPPER: The following announcement addresses the issue of conflict of interest with respect to this meeting and is made as part of the record to preclude even the appearance of such.

Based on the agenda, it has been determined that the topics of today's meeting are issues of broad applicability and there are no products being approved. Unlike issues before a committee in which a particular product is discussed, issues of broader applicability involved many industrial sponsors and academic institutions. All special government employees have been screened for their financial interests as they may apply to the general topics at hand.

To determine if any of the conflict of interest existed, the agency has reviewed the agenda and all relevant financial interests reported by the meeting participants. The Food and Drug Administration has granted general matter waivers to the special government employees participating in this meeting who require a waiver under Title 18, United States Code Section 208.

A copy of the waiver statements may be obtained by submitting a written request of the agency's Freedom of Information Office, Room 12A-30 of the Parklawn Building.

Because general topics impact so many entities, it is not practical to recite all potential conflicts of interest as they apply to each member, consultant, and guest speaker. FDA acknowledges that there may be potential conflicts of interest, but because of the general nature of the discussions before the committee, these potential conflicts are mitigated.

With respect to FDA's invited industry representative, we would like to disclose that Dr. Annette Stemhagen is participating in this meeting as a non-voting industry representative acting on behalf of regulated industry.

Dr. Stemhagen's role on this committee is to represent industry interests in general, and not any one particular company. Dr. Stemhagen is vice president of Strategic Development Services for Covance Periapproval Services, Inc.

In the event that the discussions involve any other products of firm not already on the agenda for which FDA participants have a financial interest, the participants involved and their exclusion will be noted for the record.

With respect to all other participants, we ask in the interest of fairness that they address any current or previous financial involvement with any first whose products they may wish to comment upon.

Thank you.

DR. WOOD: Thank you.

Let's go right to the first speaker, Dr. Platt, who is going to tell us about observational studies.

Weitz & Luxenberg is no longer accepting Bextra cases.

see also:

Conflict of Interest Your Bextra Side Effects Lawyer - Vioxx, Celebrex & Bextra FDA - Conflict of Interest Statement
Bextra side effects lawyer - the complete transcript of the FDA meeting

Questions Your Bextra Side Effects Lawyer - Vioxx, Celebrex & Bextra FDA - Questions
Bextra side effects lawyer - the complete transcript of the FDA meeting

FDA Transcript - Day 2 Vioxx, Celebrex & Bextra FDA Transcript
Your lawyer provides the complete transcript of the FDA meeting.